Evidence map›Paper›PMID 30362387›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2019

Synthesis and cytotoxic activities of novel copper and silver complexes of 1,3-diaryltriazene-substituted sulfonamides.

Dilek Canakci, Ismail Koyuncu, Nabih Lolak, Mustafa Durgun, Suleyman Akocak, Claudiu T Supuran

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. New Copper Complexes with Antibacterial and Cytotoxic Activity.International journal of molecular sciences · 2023
    Article
  6. Biological potential of copper complexes: a review.Turkish journal of chemistry · 2022
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Dilek Canakcia Department of Chemistry , Vocational School of Technical Sciences, Adiyaman University , Adiyaman , Turkey.
Ismail Koyuncub Faculty of Medicine , Department of Biochemistry , Harran University , Sanliurfa , Turkey.
Nabih Lolakc Faculty of Pharmacy , Department of Pharmaceutical Chemistry , Adiyaman University , Adiyaman, Turkey.
Mustafa Durgund Faculty of Arts and Sciences , Deparment of Chemistry , Harran University , Sanliurfa , Turkey.
Suleyman Akocakc Faculty of Pharmacy , Department of Pharmaceutical Chemistry , Adiyaman University , Adiyaman, Turkey.
Claudiu T Supurane NEUROFARBA Department, Sezione di Scienze Farmaceutiche , Università degli Studi di Firenze , Florence , Italy.ORCID http://orcid.org/0000-0003-4262-0323
Adıyaman University · TRHarran University · TRUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a series of 10 novel copper (II) and silver complexes of 1,3-diaryltriazene-substituted sulfonamides was synthesised. All the synthesised ligands and their metal complexes were assessed for in vitro cytotoxicity against human colorectal adenocarcinoma (DLD-1), cervix carcinoma (HeLa), breast adenocarcinoma (MDA-MB-231), colon adenocarcinoma (HT-29), endometrial adenocarcinoma (ECC-1), prostate cancer (DU-145 and PC-3), normal embryonic kidney (HEK-293), normal prostate epithelium (PNT-1A), and normal retinal pigment epithelium (ARPE-19) cells. Most of the metal complexes from the series showed to be more active against all cancerous cells than the uncomplexed 1,3-diaryltriazene-substituted sulfonamides, and lower cytotoxic effects observed on normal cells. Most of the Cu (II) and Ag (I) metal complexes from the presented series showed high cytotoxic activity against HeLa cells with IC

Indexed as

Antineoplastic AgentsCell ProliferationCells, CulturedCell SurvivalCopperDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureSilverStructure-Activity RelationshipSulfanilamidesTriazenesAntineoplastic AgentsCopperSilverSulfanilamidesTriazenescancer cellscytotoxicityMetal complexessulfonamidestriazene

Identifiers

PMID30362387
PMCPMC6211257
OpenAlexW2898534129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.